Genes and gastric cancer.
Gastric cancer remains quite a common malignancy and counts among the most important causes of cancer-related death worldwide. Although the pathogenesis is multifactorial, familial aggregation in a significant proportion of cases suggests the importance of genetic predisposition. The association between the E-cadherin/CDH1 gene germline mutations and the development of diffuse gastric cancer was the first evidence for a molecular basis of gastric cancer in predisposed families and led many authorities in the world to produce guidelines regarding the management of such families members. The recent advances in genetics resulted in the discovery of numerous genetic events occurring during the course of gastric carcinogenesis (activation of oncogenes, silencing of tumor suppressor genes, mutations in DNA-repairing genes) and contributed to a better understanding in pathogenesis. Many genetic changes described have been found to affect tumor's biological behavior. In this article the authors attempt a review of all the molecular alterations in gastric cancer described in the literature and their impact on the management of patients with an inherited predisposition to gastric cancer. The promising role of gene therapy in the treatment of gastric cancer in the near future is also commented on.
Kyrlagkitsis
Ioannis
I
Gastroenterology Department, Tzanio Hospital, Pireus, Greece. ikyr@mycosmos.gr
Karamanolis
D G
DG
D015820:Cadherins / Q000235:genetics; D002237:Carbohydrate Dehydrogenases / Q000235:genetics; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000235:genetics; D005743:Gastrectomy; D020022:Genetic Predisposition to Disease; D015316:Genetic Therapy; D018095:Germ-Line Mutation; D006801:Humans; D019656:Loss of Heterozygosity; D018895:Microsatellite Repeats / Q000235:genetics; D011379:Prognosis; D013274:Stomach Neoplasms / Q000235:genetics* / Q000601:surgery / Q000628:therapy
D015820:Cadherins; D002237:Carbohydrate Dehydrogenases; C019859:cellobiose-quinone oxidoreductase